Safety and immunogenicity of prepandemic H5N1 influenza vaccines: A systematic review of the literature

Vaccine

Volumn 28, Issue 26, 2010, Pages 4328-4334

  Prieto Lara, Elisa ^a   Llanos Méndez, Aurora ^a  

^a Andalusian Agency for Health Technology Assessment Spain   (Spain)

Author keywords

Avian influenza; Immunogenicity; Influenza A virus; Prepandemic vaccines; Safety; Subtype H5N1; Systematic review

Indexed keywords

ALUMINUM HYDROXIDE; AVIAN INFLUENZA VACCINE; BK PIFA; FLUVAL H5N1; HEMAGGLUTININ; HOKKEN; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; PANFLU; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLERGIC REACTION; ARTICLE; AVIAN INFLUENZA; CLINICAL TRIAL; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EMULSION; FATIGUE; HUMAN; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; INFORMATION RETRIEVAL; INJECTION SITE PAIN; LOW DRUG DOSE; PRIORITY JOURNAL; QUALITY CONTROL; SYSTEMATIC REVIEW;

HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; SAFETY;

EID: 77952742210     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.068     Document Type: Article

References (28)

1. ® at http://www.webcitation.org/5k4lKjloU) [accessed 16.07.09].
2. World Health Organization (WHO). Pandemic Influenza Preparedness and Response. A WHO guidance document. Geneva: WHO, Global Influenza Programme; 2009. p. 62. ISBN: 978 92 4 15 4768 0.
3. ® at http://www.webcitation.org/5k4XbyoYO) [accessed 09.07.09].
4. Manzoli L., Salanti G., De Vito C., Boccia A., Ioannidis J.P.A., and Villari P. Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. Lancet Infect Dis 9 8 (2009) 482-492
5. Palache B. New vaccine approaches for seasonal and pandemic influenza. Vaccine 26 (2008) 6232-6236
6. ® at http://www.webcitation.org/5k1aL3EsI) [accessed 08.07.09].
7. European Medicines Agency (EMEA). CHPM Assessment Report for Prepandrix, Report No. EMEA/287373/2008. London: EMEA; 2008. p. 34.
8. ® at http://www.webcitation.org/5k4f5Yf4J) [accessed 19.08.09].
9. ® at http://www.webcitation.org/5k4fVwt0B) [accessed 19.08.09].
10. ® at http://www.webcitation.org/5k4firbvp) [accessed 20.08.09].
11. ® at http://www.webcitation.org/5k4fyEjKv) [accessed 20.08.09].
12. ® at http://www.webcitation.org/5k4d7TKpp) [accessed 23.07.09].
13. ® at http://www.webcitation.org/5k4dBfXKh) [accessed 23.07.09].
14. Vajo Z., Kosa L., Szilvasy I., Pauliny Z., Bartha K., Visontay I., et al. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr Infect Dis J 27 12 (2008) 1052-1056
15. ® at http://www.webcitation.org/5k4eRUcXs) [accessed 20.08.09].
16. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
17. ® at http://www.webcitation.org/5lqsRr5Jn) [accessed 17.08.09].
18. ® at http://www.webcitation.org/5k4obF8Y6) [accessed 07.07.09].
19. ECRI Institute. Vaccines for avian influenza [Health Technology Forecast]; 2009, ECRI Institute.
20. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
21. Rümke H.C., Bayas J.M., de Jr. J., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26 19 (2008) 2378-2388
22. Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48 8 (2009) 1087-1095
23. Caldwell D.M., Ades A.E., and Higgins J.P.T. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331 (2005) 897-900
24. European Medicines Agency (EMEA). Guideline on influenza vaccines prepared from viruses with the potencial to cause a pandemic and intended for use outside of the core dossier context, Report No. EMEA/CHMP/VWP/263499/2006. London: EMEA, Committee for Human Medicinal Products (CHMP); 2007 January 24. p. 11.
25. European Medicines Agency (EMEA). Note for guidance on harmonization of requirements for influenza vaccines, Report No. CPMP/BWP/214/96. London: EMEA, Committee for Propietary Medicinal Products (CPMP); 1997 March 12. p. 18.
26. CDC. Use of Influenza A (H1N1) 2009 monovalent vaccine. Recommendations of the Advisory Committee on Inmunization Practices (ACIP). MMWR 58 (2009) 1-8
27. Johansen K., Nicoll A., Ciancio B.C., and Kramarz P. Pandemic influenza A (H1N1) 2009 vaccines in the European Union. Euro Surveill 14 41 (2009). http://www.eurosurveillance.org/ViewArticle.aspx%3FArticleId=19361 pii=19361. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19361
28. ®-Adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4 2 (2009) e4384